双特异性抗体市场－全球产业规模、份额、趋势、机会和预测：按适应症、地区和竞争格局划分，2021-2031年

全球双特异性抗体市场预计将从 2025 年的 74.4 亿美元成长到 2031 年的 127.6 亿美元，年复合成长率为 9.41%。

这些疗法是经过特殊设计的蛋白质，能够同时结合两种不同的抗原或抗原决定位，从而提供全新的作用机制，例如引导免疫效应细胞到达肿瘤部位。这种双标靶化能力，加上蛋白质工程技术的进步克服了单特异性抗体的局限性，正推动其在肿瘤学和自体免疫疾病治疗领域的应用日益广泛。抗体学会指出，2023年美国和欧洲监管机构核准了首批四种双特异性抗体，凸显了该领域快速的商业性化进展。

然而，该市场在生产复杂性和扩充性方面面临重大挑战。合成双特异性抗体需要复杂的製程以确保正确的链配对和稳定性，这导致其产量低于传统单株抗体，成本更高。这些技术壁垒使得规模化生产困难，并需要严格的品管措施。这些要求可能会延迟监管核准，增加最终治疗成本，并阻碍其广泛市场准入。

市场驱动因素

生物技术领域的策略合作和授权协议正在从根本上改变产业结构，製药巨头积极收购外部创新成果以增强其免疫肿瘤产品组合。主要企业透过收购成熟的双特异性抗体平台来降低早期研发风险，这些平台能够同时针对多种疾病路径。这一趋势正在催生一个生态系统，在这个系统中，中小型生物技术公司可以获得必要的资金，而大型公司则可以为其研发管线锁定有前景的候选药物。例如，根据 Fierce Biotech 报导，默克于 2024 年 1 月签署了一项最终协议，以约 6.8 亿美元收购 Harpoon Therapeutics，从而进入许可权该公司专有的 T 细胞活化技术。

新型双特异性疗法的监管核准激增，进一步推动了市场发展，因为这些复杂的治疗方法已在广泛的患者群体中展现出安全性和有效性。随着生产和临床通讯协定标准化的推进，监管机构正在加快核准，这些治疗方法正从实验阶段走向主流临床实践。据抗体协会称，包括tarlatamab和zanidatamab在内的几种新型双特异性抗体药物于2024年首次核准。监管方面的成功凸显了其商业性可行性，罗氏公司在2024年10月宣布，其双特异性抗体药物Vabysmo在当年九个月的年销售额已达到28亿瑞士法郎，便印证了这一点。

市场挑战

生产流程的复杂性和规模化生产的困难仍然是全球双特异性抗体市场扩张的主要障碍。与标准单株抗体不同，双特异性抗体需要精确设计两个不同的结合位点，而这个过程本身就增加了错配和产品不稳定的风险。这种技术复杂性通常会导致产量降低和杂质含量升高，从而直接推高产品成本。因此，製造商在将生产规模扩大到商业水平时面临许多困难，而高昂的价格限制了患者获得治疗的机会，阻碍了市场渗透。

此外，这些生产挑战需要严格的品管措施，导致研发週期延长和监管批准延迟。为确保这些复杂分子的稳定性和安全性，需要进行严格的审查，这也导致了后期研发阶段的高失败率。根据抗体协会估计，到2024年，抗体疗法的整体核准成功率预计在14%至32%之间，这反映出巨大的研发风险和监管障碍阻碍了此类复杂治疗方法的快速商业化，并减缓了市场成长速度。

市场趋势

出于提高病患就医便利性和优化医疗资源利用的需求，市场正明显转向皮下给药製剂。製造商正积极重新设计静脉注射疗法，使其适用于皮下给药，旨在缩短治疗时间、简化给药流程并减轻慢性治疗方法的后勤负担。这一趋势得到了临床证据的支持。强生表示，2024年5月公布的III期PALOMA-3试验数据显示，与静脉注射注射相比，皮下注射的阿米伐他单抗可将液体相关反应减少五分之一，并将给药时间缩短至约5分钟。

同时，随着研发公司将这些治疗方法转向高发自自体免疫疾病领域，一个显着的趋势正在显现：适应症范围从肿瘤领域向其他领域多元化发展。虽然肿瘤仍然是主要领域，但精准清除致病性B细胞和调节双重发炎路径的能力正在推动对非癌症领域（例如异位性皮肤炎和类风湿性关节炎）的投资增加。默克在2024年8月达成协议，以最高13亿美元收购Curon Biopharmaceuticals公司处于临床阶段的双特异性抗体CN201，就是这项策略扩张的典型例子。该公司明确计划将该资产用于治疗B细胞相关的自体免疫疾病。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球双特异性抗体市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 适应症（癌症、发炎/自体免疫疾病及其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美双特异性抗体市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲双特异性抗体市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区双特异性抗体市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲双特异性抗体市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲双特异性抗体市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球双特异性抗体市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Amgen Inc
• F. Hoffmann-La Roche Ltd
• Genentech Inc
• Akeso Inc
• Johnson & Johnson Private Limited
• Taisho Pharmaceutical Co Ltd
• Immunocore Ltd

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Bispecific Antibodies Market is projected to expand from USD 7.44 Billion in 2025 to USD 12.76 Billion by 2031, reflecting a compound annual growth rate of 9.41%. These therapeutics are engineered proteins capable of binding simultaneously to two distinct antigens or epitopes, offering novel mechanisms of action such as redirecting immune effector cells to tumor sites. This dual-targeting capability drives their increasing adoption in oncology and autoimmune disease treatments, supported by advances in protein engineering that surpass the limitations of monospecific options. The rapid commercial progression of this sector was highlighted by The Antibody Society, which noted that regulatory agencies in the United States and Europe granted first approvals to four bispecific antibodies in 2023.

However, the market faces substantial challenges regarding manufacturing complexity and production scalability. Synthesizing bispecific antibodies involves intricate processes to ensure correct chain pairing and stability, often resulting in lower yields and higher costs compared to conventional monoclonal antibodies. These technical hurdles make upscaling production difficult and necessitate stringent quality control measures. Such requirements can delay regulatory clearance and inflate the final cost of therapy, potentially impeding widespread market accessibility.

Market Driver

Strategic collaborations and licensing agreements within the biotechnology sector are fundamentally reshaping the landscape as pharmaceutical giants aggressively acquire external innovation to strengthen their immuno-oncology portfolios. Major players are mitigating early-stage development risks by purchasing established bispecific platforms capable of targeting multiple disease pathways simultaneously. This trend fosters an ecosystem where smaller biotechs receive essential capital while larger firms secure high-potential candidates for their pipelines. For example, according to Fierce Biotech, Merck entered a definitive agreement in January 2024 to acquire Harpoon Therapeutics for approximately $680 million to access its proprietary T-cell engager technology.

A surge in regulatory approvals for novel bispecific therapies further drives the market, validating the safety and efficacy of these complex modalities for broader patient populations. As manufacturing and clinical protocols standardize, regulatory bodies are accelerating authorizations, moving these treatments from experimental stages to mainstream practice. The Antibody Society noted that in 2024, agencies granted first approvals to several new bispecifics, including tarlatamab and zanidatamab. This regulatory success supports commercial viability, as evidenced by Roche's report in October 2024 that sales of its bispecific medicine Vabysmo reached CHF 2.8 billion in the first nine months of the year.

Market Challenge

The complexity of manufacturing and production scalability remains a significant barrier to the expansion of the Global Bispecific Antibodies Market. Unlike standard monoclonal antibodies, bispecific formats require the precise engineering of two distinct binding arms, a process that inherently increases the risk of chain mispairing and product instability. These technical intricacies frequently result in lower production yields and higher levels of impurities, which directly escalate the cost of goods sold. Consequently, manufacturers face difficulties in upscaling processes to commercial levels, leading to high pricing structures that limit therapy accessibility and market penetration.

Moreover, these production hurdles necessitate stringent quality control measures that extend development timelines and delay regulatory decision-making. The rigorous scrutiny required to ensure the stability and safety of these complex molecules contributes to a high attrition rate during late-stage development. According to The Antibody Society, the overall approval success rates for antibody therapeutics in 2024 were estimated to range between 14% and 32%, reflecting the substantial developmental risks and regulatory hurdles that impede the rapid commercialization of such complex modalities and slow the market's growth trajectory.

Market Trends

The market is experiencing a definitive shift towards subcutaneous delivery formulations, driven by the need to enhance patient convenience and optimize healthcare resource utilization. Manufacturers are actively re-engineering intravenous therapies into subcutaneous formats to significantly reduce chair time and administration complexity, addressing the logistical burdens of chronic treatment regimens. This trend is supported by clinical evidence; according to Johnson & Johnson, data from the Phase 3 PALOMA-3 study in May 2024 demonstrated that the subcutaneous formulation of amivantamab reduced infusion-related reactions five-fold compared to the intravenous version while shortening administration time to approximately five minutes.

Concurrently, there is a major trend regarding the diversification of indications beyond oncology, as pharmaceutical developers pivot these modalities toward high-prevalence autoimmune disorders. While oncology remains a key area, the ability of bispecific antibodies to precisely deplete pathogenic B-cells or modulate dual inflammatory pathways has triggered increased investment in non-cancer applications such as atopic dermatitis and rheumatoid arthritis. This strategic expansion is exemplified by Merck & Co.'s agreement in August 2024 to acquire Curon Biopharmaceutical's clinical-stage bispecific antibody CN201 for a potential $1.3 billion, explicitly aiming to leverage the asset for treating B-cell associated autoimmune diseases.

Key Market Players

• Amgen Inc
• F. Hoffmann-La Roche Ltd
• Genentech Inc
• Akeso Inc
• Johnson & Johnson Private Limited
• Taisho Pharmaceutical Co Ltd
• Immunocore Ltd

Report Scope

In this report, the Global Bispecific Antibodies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bispecific Antibodies Market, By Indication

• Cancer
• Inflammatory & Autoimmune Disorders
• Others

Bispecific Antibodies Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bispecific Antibodies Market.

Available Customizations:

Global Bispecific Antibodies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bispecific Antibodies Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
  • 5.2.2. By Region
  • 5.2.3. By Company (2025)
• 5.3. Market Map

6. North America Bispecific Antibodies Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication
  • 6.2.2. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Bispecific Antibodies Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
  • 6.3.2. Canada Bispecific Antibodies Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
  • 6.3.3. Mexico Bispecific Antibodies Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication

7. Europe Bispecific Antibodies Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Bispecific Antibodies Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
  • 7.3.2. France Bispecific Antibodies Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
  • 7.3.3. United Kingdom Bispecific Antibodies Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
  • 7.3.4. Italy Bispecific Antibodies Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
  • 7.3.5. Spain Bispecific Antibodies Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication

8. Asia Pacific Bispecific Antibodies Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Bispecific Antibodies Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
  • 8.3.2. India Bispecific Antibodies Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
  • 8.3.3. Japan Bispecific Antibodies Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
  • 8.3.4. South Korea Bispecific Antibodies Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indication
  • 8.3.5. Australia Bispecific Antibodies Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indication

9. Middle East & Africa Bispecific Antibodies Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Bispecific Antibodies Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
  • 9.3.2. UAE Bispecific Antibodies Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
  • 9.3.3. South Africa Bispecific Antibodies Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication

10. South America Bispecific Antibodies Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Bispecific Antibodies Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
  • 10.3.2. Colombia Bispecific Antibodies Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
  • 10.3.3. Argentina Bispecific Antibodies Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Bispecific Antibodies Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Amgen Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. F. Hoffmann-La Roche Ltd
• 15.3. Genentech Inc
• 15.4. Akeso Inc
• 15.5. Johnson & Johnson Private Limited
• 15.6. Taisho Pharmaceutical Co Ltd
• 15.7. Immunocore Ltd

16. Strategic Recommendations

17. About Us & Disclaimer